XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020)

XOMA Royalty's (XOMA) quarterly Asset Writedowns and Impairment came in at -$1.4 million in Q4 2020, down 199.36% quarter-over-quarter from $1.4 million in Q1 2020.

XOMA Royalty (XOMA) Asset Writedowns and Impairment (2012 - 2020) Analysis & Trends

XOMA Royalty has disclosed Asset Writedowns and Impairment across 2 years of filings, most recently posting -$1.4 million for Q4 2020.

  • Asset Writedowns and Impairment for Q4 2020 came in at -$1.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $9000.0 (changed N/A YoY), and the FY2023 annual result was $14.3 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment came in at -$1.4 million for Q4 2020 at XOMA Royalty, down from $1.4 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q1 2020 to a low of -$1.4 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn -
7 Psyence Biomedical 227.32 Bn 227.31 Bn -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn
9 Abivax 91.71 Bn 91.71 Bn -
10 XOMA Royalty 5.48 Mn -60.60 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2020 -1.40 Mn
Dec 31, 2020 -1.40 Mn
Mar 31, 2020 1.41 Mn
Mar 31, 2020 1.41 Mn
Dec 31, 2012 219,000.00
Dec 31, 2012 219,000.00
Sep 30, 2012 160,000.00
Sep 30, 2012 160,000.00
Jun 30, 2012 374,000.00
Jun 30, 2012 374,000.00
Mar 31, 2012 1.71 Mn
Mar 31, 2012 1.71 Mn